Enliven Therapeutics ELVN Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's accrued expenses and other liabilities?
- Enliven Therapeutics (ELVN) reported accrued expenses and other liabilities of -$4.47M in Q1 2026.
- How has Enliven Therapeutics's accrued expenses and other liabilities changed year-over-year?
- Enliven Therapeutics's accrued expenses and other liabilities decreased by 79.0% year-over-year, from -$2.5M to -$4.47M.
- What is the long-term trend for Enliven Therapeutics's accrued expenses and other liabilities?
- Over 3 years (2021 to 2024), Enliven Therapeutics's accrued expenses and other liabilities has grown at a -14.2% compound annual growth rate (CAGR), from $393K to -$248K.